MX2023008515A - Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd). - Google Patents
Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd).Info
- Publication number
- MX2023008515A MX2023008515A MX2023008515A MX2023008515A MX2023008515A MX 2023008515 A MX2023008515 A MX 2023008515A MX 2023008515 A MX2023008515 A MX 2023008515A MX 2023008515 A MX2023008515 A MX 2023008515A MX 2023008515 A MX2023008515 A MX 2023008515A
- Authority
- MX
- Mexico
- Prior art keywords
- mds
- ferroportin
- inhibitors
- treatment
- myelodysplastic syndromes
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091006976 SLC40A1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
La invención se refiere al uso de compuestos inhibidores de la ferroportina de la fórmula general (I) para tratar síndromes mielodisplásicos (SMD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139586P | 2021-01-20 | 2021-01-20 | |
| EP21170897 | 2021-04-28 | ||
| PCT/EP2022/051108 WO2022157185A1 (en) | 2021-01-20 | 2022-01-19 | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008515A true MX2023008515A (es) | 2023-07-27 |
Family
ID=80168169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008515A MX2023008515A (es) | 2021-01-20 | 2022-01-19 | Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd). |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4281072A1 (es) |
| JP (1) | JP2024504349A (es) |
| KR (1) | KR20230134476A (es) |
| AU (1) | AU2022209384A1 (es) |
| CA (1) | CA3205845A1 (es) |
| IL (1) | IL304305A (es) |
| MX (1) | MX2023008515A (es) |
| WO (1) | WO2022157185A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024083980A1 (en) | 2022-10-21 | 2024-04-25 | Vifor (International) Ag | Bicyclic ferroportin inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2787994A4 (en) | 2011-12-09 | 2015-08-26 | Ferrokin Biosciences Inc | ORAL FORMULATIONS FOR TREATING METAL OVERLOAD |
| CN107847562A (zh) | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
| WO2017068089A2 (en) | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| EP3894416B1 (en) | 2018-12-13 | 2022-11-09 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
-
2022
- 2022-01-19 EP EP22702187.0A patent/EP4281072A1/en active Pending
- 2022-01-19 KR KR1020237021957A patent/KR20230134476A/ko unknown
- 2022-01-19 CA CA3205845A patent/CA3205845A1/en active Pending
- 2022-01-19 MX MX2023008515A patent/MX2023008515A/es unknown
- 2022-01-19 AU AU2022209384A patent/AU2022209384A1/en active Pending
- 2022-01-19 JP JP2023544155A patent/JP2024504349A/ja active Pending
- 2022-01-19 WO PCT/EP2022/051108 patent/WO2022157185A1/en active Application Filing
-
2023
- 2023-07-06 IL IL304305A patent/IL304305A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022209384A1 (en) | 2023-06-29 |
| IL304305A (en) | 2023-09-01 |
| CA3205845A1 (en) | 2022-07-28 |
| EP4281072A1 (en) | 2023-11-29 |
| KR20230134476A (ko) | 2023-09-21 |
| WO2022157185A1 (en) | 2022-07-28 |
| JP2024504349A (ja) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
| SA522433087B1 (ar) | Sos1 مثبطات | |
| EA201990699A1 (ru) | Спиробициклические ингибиторы взаимодействия менин–mll | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| MX2019002959A (es) | Inhibidores biciclicos condensados de la interaccion de menina-mll. | |
| MX2022001019A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). | |
| MX2011012369A (es) | Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| JOP20190285A1 (ar) | استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد | |
| MX2019002962A (es) | Inhibidores espirobiciclicos de la interaccion de menina-mll. | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| MX2023008515A (es) | Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd). | |
| EA201791365A1 (ru) | Замещенный пиридил-циклоалкил-карбоновые кислоты, содержащие их композиции и их медицинское применение | |
| MX2022000782A (es) | Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt). |